Immune responses involve coordination across cell types and tissues. However, studies in cancer immunotherapy have focused heavily on local immune responses in the tumor microenvironment. To investigate immune activity more broadly, we performed an organism-wide study in genetically engineered cancer models using mass cytometry. We analyzed immune responses in several tissues after immunotherapy by developing intuitive models for visualizing single-cell data with statistical inference. Immune activation was evident in the tumor and systemically shortly after effective therapy was administered. However, during tumor rejection, only peripheral immune cells sustained their proliferation. This systemic response was coordinated across tissues and required for tumor eradication in several immunotherapy models. An emergent population of peripheral CD4 T cells conferred protection against new tumors and was significantly expanded in patients responding to immunotherapy. These studies demonstrate the critical impact of systemic immune responses that drive tumor rejection.

Spitzer, M.h., Carmi, Y., Reticker-Flynn, N.e., Kwek, S.s., Madhireddy, D., Martins, M.m., et al. (2017). Systemic immunity is required for effective cancer immunotherapy. CELL, 168(3), 487-502.e15 [10.1016/j.cell.2016.12.022].

Systemic immunity is required for effective cancer immunotherapy

Gherardini, Pier Federico;
2017-01-26

Abstract

Immune responses involve coordination across cell types and tissues. However, studies in cancer immunotherapy have focused heavily on local immune responses in the tumor microenvironment. To investigate immune activity more broadly, we performed an organism-wide study in genetically engineered cancer models using mass cytometry. We analyzed immune responses in several tissues after immunotherapy by developing intuitive models for visualizing single-cell data with statistical inference. Immune activation was evident in the tumor and systemically shortly after effective therapy was administered. However, during tumor rejection, only peripheral immune cells sustained their proliferation. This systemic response was coordinated across tissues and required for tumor eradication in several immunotherapy models. An emergent population of peripheral CD4 T cells conferred protection against new tumors and was significantly expanded in patients responding to immunotherapy. These studies demonstrate the critical impact of systemic immune responses that drive tumor rejection.
26-gen-2017
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/11 - BIOLOGIA MOLECOLARE
English
cancer immunotherapy; immune responses; immunotherapy; mass cytometry; secondary lymphoid organs; single-cell analysis; systems immunology; tumor immunology; tumor microenvironment
Spitzer, M.h., Carmi, Y., Reticker-Flynn, N.e., Kwek, S.s., Madhireddy, D., Martins, M.m., et al. (2017). Systemic immunity is required for effective cancer immunotherapy. CELL, 168(3), 487-502.e15 [10.1016/j.cell.2016.12.022].
Spitzer, Mh; Carmi, Y; Reticker-Flynn, Ne; Kwek, Ss; Madhireddy, D; Martins, Mm; Gherardini, Pf; Prestwood, Tr; Chabon, J; Bendall, Sc; Fong, L; Nolan...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
nihms842747 (1).pdf

accesso aperto

Tipologia: Documento in Pre-print
Licenza: Copyright dell'editore
Dimensione 3.91 MB
Formato Adobe PDF
3.91 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/312297
Citazioni
  • ???jsp.display-item.citation.pmc??? 455
  • Scopus 675
  • ???jsp.display-item.citation.isi??? 673
social impact